gentamicin has been researched along with Carcinoma, Epidermoid in 12 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Excerpt | Relevance | Reference |
---|---|---|
"Corynebacterium diphtheriae, generally considered an extracellular coloniser, was evaluated for its ability to enter and survive within HEp-2 monolayers by gentamicin protection assay." | 3.71 | Intracellular viability of toxigenic Corynebacterium diphtheriae strains in HEp-2 cells. ( Andrade, AF; Fonseca, LS; Formiga, LC; Hirata, R; Mattos-Guaraldi, AL; Monteiro-Leal, LH; Nagao, PE; Napoleão, F, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (33.33) | 18.2507 |
2000's | 5 (41.67) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Martínez-Doménech, Á | 1 |
García-Legaz Martínez, M | 1 |
Magdaleno-Tapial, J | 1 |
Valenzuela-Oñate, C | 1 |
Pérez-Pastor, G | 1 |
Pérez-Ferriols, A | 1 |
Yang, CH | 1 |
Chew, KY | 1 |
Solomkin, JS | 1 |
Lin, PY | 1 |
Chiang, YC | 1 |
Kuo, YR | 1 |
Thatcher, N | 1 |
Hirsch, FR | 1 |
Luft, AV | 1 |
Szczesna, A | 1 |
Ciuleanu, TE | 1 |
Dediu, M | 1 |
Ramlau, R | 1 |
Galiulin, RK | 1 |
Bálint, B | 1 |
Losonczy, G | 1 |
Kazarnowicz, A | 1 |
Park, K | 1 |
Schumann, C | 1 |
Reck, M | 1 |
Depenbrock, H | 1 |
Nanda, S | 1 |
Kruljac-Letunic, A | 1 |
Kurek, R | 1 |
Paz-Ares, L | 1 |
Socinski, MA | 1 |
Hirata, R | 1 |
Napoleão, F | 1 |
Monteiro-Leal, LH | 1 |
Andrade, AF | 1 |
Nagao, PE | 1 |
Formiga, LC | 1 |
Fonseca, LS | 1 |
Mattos-Guaraldi, AL | 1 |
Duncan, GG | 1 |
Epstein, JB | 1 |
Tu, D | 1 |
El Sayed, S | 1 |
Bezjak, A | 1 |
Ottaway, J | 1 |
Pater, J | 1 |
Campbell, RM | 1 |
Perlis, CS | 1 |
Fisher, E | 1 |
Gloster, HM | 1 |
Inagaki, T | 2 |
Matsuwari, S | 2 |
Shimada, K | 2 |
Abe, N | 1 |
Takahashi, R | 2 |
Maeda, S | 2 |
Fujie, K | 1 |
Berardi, RS | 1 |
Ena, P | 1 |
Lissia, M | 1 |
Doneddu, GM | 1 |
Campus, GV | 1 |
Ji, ZW | 1 |
Oku, N | 1 |
Komori, T | 1 |
El-Sayed, S | 1 |
Epstein, J | 1 |
Minish, E | 1 |
Burns, P | 1 |
Hay, J | 1 |
Laukkanen, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients Who Receiving Radical Concurrent Chemoradiotherapy and Immunotherapy: a Prospective, Randomized Controlled, Multicenter P[NCT04980716] | Phase 3 | 524 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial[NCT03542461] | Phase 3 | 125 participants (Actual) | Interventional | 2017-09-25 | Active, not recruiting | ||
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer[NCT00981058] | Phase 3 | 1,093 participants (Actual) | Interventional | 2010-01-07 | Active, not recruiting | ||
Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer[NCT01066741] | Phase 3 | 78 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to insufficient recruitment, the planed sample size appears not achievable) | ||
The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). (NCT00981058)
Timeframe: Baseline, Cycle 6 (Cycle = 3 Weeks)
Intervention | units on a scale (Mean) |
---|---|
Necitumumab + Gemcitabine + Cisplatin | -0.0053 |
Gemcitabine + Cisplatin | -0.0083 |
Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method. (NCT00981058)
Timeframe: Randomization to Death from Any Cause (Up to 31 Months)
Intervention | Months (Median) |
---|---|
Necitumumab + Gemcitabine + Cisplatin | 11.5 |
Gemcitabine + Cisplatin | 9.9 |
ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a >=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100. (NCT00981058)
Timeframe: Baseline to Measured Progressive Disease (Up to 31 Months)
Intervention | percentage of participants (Number) |
---|---|
Necitumumab + Gemcitabine + Cisplatin | 31.2 |
Gemcitabine + Cisplatin | 28.8 |
PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits. (NCT00981058)
Timeframe: Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)
Intervention | months (Median) |
---|---|
Necitumumab + Gemcitabine + Cisplatin | 5.7 |
Gemcitabine + Cisplatin | 5.5 |
TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study. (NCT00981058)
Timeframe: Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)
Intervention | Months (Median) |
---|---|
Necitumumab + Gemcitabine + Cisplatin | 4.3 |
Gemcitabine + Cisplatin | 3.6 |
The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively. (NCT00981058)
Timeframe: Baseline, Cycle 6 (Cycle = 3 Weeks)
Intervention | millimeter (mm) (Mean) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Loss of Appetite (n=304, 242) | Fatigue (n=302, 242) | Cough (n=303, 243) | Dyspnea (n=305, 244) | Pain (n=302, 243) | Overall Symptoms (n=303, 242) | Interference (n=306,241) | Quality of Life (n=305, 243) | Average Symptom Burden Index (ASBI) (n=294, 234) | LCSS Total Score (n=290, 228) | |
Gemcitabine + Cisplatin | 1.5 | 3.5 | -9.1 | -1.8 | -2.2 | -0.6 | 2.2 | -1.6 | -1.5 | -0.8 |
Necitumumab + Gemcitabine + Cisplatin | 1.8 | 6.3 | -7.8 | -2.8 | -3.3 | -0.3 | 3.8 | -0.3 | -1.9 | -0.8 |
A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point. (NCT00981058)
Timeframe: Baseline through 31 Months
Intervention | participants (Number) | |
---|---|---|
Participants with at least 1 positive titer | Neutralizing antibody detected | |
Necitumumab + Gemcitabine + Cisplatin | 81 | 5 |
EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of <200 and participants with a high EGFR expression defined by a H-score of cutoff value of >=200. (NCT00981058)
Timeframe: 31 Months
Intervention | participants (Number) | |||
---|---|---|---|---|
0 | >0 | <200 | ≥200 | |
Gemcitabine + Cisplatin | 23 | 473 | 313 | 183 |
Necitumumab + Gemcitabine + Cisplatin | 24 | 462 | 295 | 191 |
(NCT00981058)
Timeframe: Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months
Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | ||||
---|---|---|---|---|---|
Predose Cycle 2 Day 1 (n=419) | Predose Cycle3 Day 1 (n=386) | Predose Cycle 4 Day 1 (n=344) | Predose Cycle 5 Day 1 (n=297) | Predose Cycle 6 Day 1 (n=262) | |
Necitumumab + Gemcitabine + Cisplatin | 52.4 | 76.6 | 94.5 | 101 | 98.5 |
1 review available for gentamicin and Carcinoma, Epidermoid
Article | Year |
---|---|
Erosive pustular dermatosis of the scalp in skin grafts: report of three cases.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 1997 |
3 trials available for gentamicin and Carcinoma, Epidermoid
8 other studies available for gentamicin and Carcinoma, Epidermoid
Article | Year |
---|---|
Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Topics: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunolog | 2019 |
Surgical site infections among high-risk patients in clean-contaminated head and neck reconstructive surgery: concordance with preoperative oral flora.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carcinoma, Squamous Cell; Clindamycin; F | 2013 |
Intracellular viability of toxigenic Corynebacterium diphtheriae strains in HEp-2 cells.
Topics: Anti-Bacterial Agents; Carcinoma, Squamous Cell; Corynebacterium diphtheriae; Diphtheria; Endocardit | 2002 |
Gentamicin ointment versus petrolatum for management of auricular wounds.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carcinoma, Basal Cell; Carcinoma, Squamous Cel | 2005 |
[Effective removal of the contaminating host fibroblasts for establishment of human-tumor cultured lines].
Topics: Aged; Animals; Carcinoma, Squamous Cell; Cell Division; Cell Separation; Culture Media; Female; Fibr | 1993 |
Establishment of human oral-cancer cell lines (KOSC-2 and -3) carrying p53 and c-myc abnormalities by geneticin treatment.
Topics: Aged; Animals; Carcinoma, Squamous Cell; Cell Division; Chromosome Aberrations; DNA, Neoplasm; Femal | 1994 |
Morbidity after abdomino-perineal resection.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Gentamicins; Humans; Perineum; Surgical Wound Infection; W | 1993 |
Establishment of a novel human squamous cell carcinoma cell line from oral primary tumor by geneticin treatment.
Topics: Animals; Carcinoma, Squamous Cell; Cytological Techniques; Gentamicins; Gingival Neoplasms; Humans; | 2000 |